MX347533B - Celulas similares a tr1 que producen il-13, y su uso. - Google Patents

Celulas similares a tr1 que producen il-13, y su uso.

Info

Publication number
MX347533B
MX347533B MX2013000115A MX2013000115A MX347533B MX 347533 B MX347533 B MX 347533B MX 2013000115 A MX2013000115 A MX 2013000115A MX 2013000115 A MX2013000115 A MX 2013000115A MX 347533 B MX347533 B MX 347533B
Authority
MX
Mexico
Prior art keywords
producing
cells
population
enriching
isolating
Prior art date
Application number
MX2013000115A
Other languages
English (en)
Other versions
MX2013000115A (es
Inventor
Foussat Arnaud
Brun Valérie
Bastian Hervé
Quattannens Brigitte
Original Assignee
Txcell *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Txcell * filed Critical Txcell *
Publication of MX2013000115A publication Critical patent/MX2013000115A/es
Publication of MX347533B publication Critical patent/MX347533B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0637Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/46433Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/46434Antigens related to induction of tolerance to non-self
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464839Allergens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)

Abstract

La presente invención se refiere a una población aislada de células Tr1 humanas, capaz de producir IL-13 cuando dichas células Tr1 humanas son activadas por los anticuerpos anti-CD3 y anti-CD28, caracterizad porque la población de células Tr1 humanas expresa CD4, un nivel bajo de CD127 y un nivel bajo de CD62L.
MX2013000115A 2010-06-30 2011-06-30 Celulas similares a tr1 que producen il-13, y su uso. MX347533B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35988510P 2010-06-30 2010-06-30
EP10368030A EP2412802A1 (en) 2010-07-29 2010-07-29 IL-13 producing TR1-like cells and use thereof
PCT/IB2011/002269 WO2012001533A2 (en) 2010-06-30 2011-06-30 Il-13 producing tr1-like cells and use thereof

Publications (2)

Publication Number Publication Date
MX2013000115A MX2013000115A (es) 2013-09-13
MX347533B true MX347533B (es) 2017-05-02

Family

ID=43099691

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000115A MX347533B (es) 2010-06-30 2011-06-30 Celulas similares a tr1 que producen il-13, y su uso.

Country Status (14)

Country Link
US (1) US20130101568A1 (es)
EP (2) EP2412802A1 (es)
JP (2) JP2013539356A (es)
KR (1) KR20130093083A (es)
CN (2) CN107189983A (es)
AU (1) AU2011273103B2 (es)
BR (1) BR112012033727A2 (es)
CA (1) CA2803779A1 (es)
CL (1) CL2012003705A1 (es)
MX (1) MX347533B (es)
NZ (1) NZ605088A (es)
RU (1) RU2013103765A (es)
WO (1) WO2012001533A2 (es)
ZA (1) ZA201209758B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3717622A1 (en) * 2017-12-01 2020-10-07 Global Life Sciences Solutions USA LLC Methods for cell enrichment and isolation
US11920119B2 (en) 2018-02-09 2024-03-05 Global Life Sciences Solutions Usa Llc Systems and methods for bioprocessing
US11932842B2 (en) 2018-02-09 2024-03-19 Global Life Sciences Solutions Usa Llc Bioprocessing apparatus
CN113461822B (zh) * 2021-05-21 2022-11-11 深圳市新产业生物医学工程股份有限公司 Scl-70抗体或其结合片段、其筛选方法及包含其的检测试剂盒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US6379670B1 (en) * 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
DE60112718T2 (de) * 2000-01-20 2006-06-29 Yeda Research And Development Co., Ltd. Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
EP1712615A1 (en) 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
US20090035798A1 (en) * 2005-04-27 2009-02-05 Harding Fiona A Methods for Reducing the Immunogenicity of Cytokines and Removal of Cell Surface Markers
EP2029729A2 (en) * 2006-05-31 2009-03-04 Genzyme Corporation Methods of using anti-thymocyte globulin and related agents
EP3431585A1 (en) * 2006-05-31 2019-01-23 The Regents of The University of California Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
EP2050814A1 (en) * 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis

Also Published As

Publication number Publication date
WO2012001533A3 (en) 2012-06-07
EP2412802A1 (en) 2012-02-01
WO2012001533A2 (en) 2012-01-05
CA2803779A1 (en) 2012-01-05
JP2017148042A (ja) 2017-08-31
JP2013539356A (ja) 2013-10-24
KR20130093083A (ko) 2013-08-21
BR112012033727A2 (pt) 2017-07-18
ZA201209758B (en) 2014-03-26
CN107189983A (zh) 2017-09-22
RU2013103765A (ru) 2014-08-10
MX2013000115A (es) 2013-09-13
AU2011273103B2 (en) 2015-04-16
EP2588595A2 (en) 2013-05-08
AU2011273103A1 (en) 2013-01-17
NZ605088A (en) 2015-05-29
CL2012003705A1 (es) 2013-12-13
CN103080303A (zh) 2013-05-01
US20130101568A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
SG196784A1 (en) Stem cell cultures
PH12015501477A1 (en) Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
MY159971A (en) Multipotent/pluripotent cells and methods
BR112013002811A8 (pt) meios básicos simplificados para cultura celular pluripotente de humano
MX2010000348A (es) Cultivo de celulas madre pluripotentes individuales.
WO2011156654A3 (en) Pathways characterization of cells
WO2010096588A3 (en) Cell culture media containing combinations of proteins
MY141039A (en) Fuel cell
WO2013006474A3 (en) Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
UA118328C2 (uk) Спосіб інтегрування екзогенних послідовностей у геном рослинної клітини
NZ703529A (en) Novel biocatalyst compositions and processes for use
WO2010111409A3 (en) Pluripotent stem cells
WO2012031280A3 (en) Identification and enrichment of cell subpopulations
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
MX2018014043A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
SG10201810830UA (en) Cell culture compositions and methods for polypeptide production
WO2011021194A3 (en) Pericyte progenitor cells and methods of generating and using same
WO2008063675A3 (en) Endodermal progenitor cells
WO2012019002A3 (en) Somatic stem cells
EP2516624A4 (en) CELL LINE 3M
EP2387609A4 (en) Nonembryonic stem cells and their use
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
WO2010097793A3 (en) Isolated populations of renal stem cells and methods of isolating and using same
EP3524672A3 (en) Reprogramming cancer cells
EP2638158A4 (en) COMPOSITIONS, CELLS, KITS AND METHODS FOR AUTOLOGOUS STEM CELL THERAPY

Legal Events

Date Code Title Description
FG Grant or registration